![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Efficacy and Safety of Emtricitabine/Tenofovir
Alafenamide vs Emtricitabine/Tenofovir Disoproxil Fumarate as a Backbone for Treatment of HIV-1 Infection in Virologically Suppressed Adults: Subgroup Analysis by 3rd Agent
|
|
|
Reported by Jules Levin
HIV Glasgow 2016 Oct 23-26
Frank Post,1 Yazdan Yazdanpanah,2 Gabriel Schembri,3 Adriano Lazzarin,4 Jacques Reynes,5 Franco Maggiolo,6 Mingjin Yan,7 Michael Abram,7 Cecilia Tran-Muchowski,7 Andrew Cheng,7 Martin Rhee7
1King's College Hospital, London, UK; 2Hôpital Bichat-Claude Bernard, Paris, France; 3The Hathersage Integrated Contraception, Sexual Health and HIV Service, Manchester, UK;
4Ospedale San Raffaele, Milano, Italy; 5Centre Hospitalier Universitaire de Montpellier, France; 6ASST Papa Giovanni XXIII, Bergamo, Italy; 7Gilead Sciences, Inc., Foster City, California, USA
![HIV1](../images/102616/102616-9/HIV1.gif)
![HIV2](../images/102616/102616-9/HIV2.gif)
![HIV3](../images/102616/102616-9/HIV3.gif)
![HIV4](../images/102616/102616-9/HIV4.gif)
![HIV5](../images/102616/102616-9/HIV5.gif)
![HIV6](../images/102616/102616-9/HIV6.gif)
![HIV7](../images/102616/102616-9/HIV7.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|